Diarrhea
393
18
28
272
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
54 trials with published results (14%)
Research Maturity
272 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.1%
24 terminated out of 393 trials
91.9%
+5.3% vs benchmark
24%
95 trials in Phase 3/4
20%
54 of 272 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 272 completed trials
Clinical Trials (393)
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Paternal Involvement in Nursing Guidance and Breastfeeding Self-Efficacy in Mothers of High-Risk Newborns
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
Impact Evaluation of Accelerating Climate-Resilient Water, Sanitation and Hygiene Services for Schools and Healthcare Facilities in Karamoja
Rural Water Filtration and Health Study
GI Alpha-Gal Study
Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer
Evaluation of a Comprehensive School Health Programme in Zambia
A Clinical Trial to Evaluate the Effects of a Fibre Supplement on Microbiome and Gut Health
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Safety of Lactobacillus LB Postbiotic in Immunocompromised Paediatric Patients With Diarrhoeal Disease
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
A Post-marketing Observational Study of Oral Cholera Vaccine
Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
Intestinal Microbiome and Chemotherapy
Wells and Enteric Disease Transmission
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.